CN105130998A - 库潘尼西的制备方法 - Google Patents

库潘尼西的制备方法 Download PDF

Info

Publication number
CN105130998A
CN105130998A CN201510618067.6A CN201510618067A CN105130998A CN 105130998 A CN105130998 A CN 105130998A CN 201510618067 A CN201510618067 A CN 201510618067A CN 105130998 A CN105130998 A CN 105130998A
Authority
CN
China
Prior art keywords
preparation
pannixi
morpholine
base propoxy
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201510618067.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105130998B (zh
Inventor
许学农
王喆
包志坚
张文件
苏健
顾新禹
薛佳
袁玉环
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SUZHOU LIXIN PHARMACEUTICAL Co.,Ltd.
Original Assignee
SUZHOU LIXIN PHARMACY CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SUZHOU LIXIN PHARMACY CO Ltd filed Critical SUZHOU LIXIN PHARMACY CO Ltd
Priority to CN201510618067.6A priority Critical patent/CN105130998B/zh
Publication of CN105130998A publication Critical patent/CN105130998A/zh
Priority to KR1020187011225A priority patent/KR102104957B1/ko
Priority to PCT/CN2016/088091 priority patent/WO2017049983A1/zh
Application granted granted Critical
Publication of CN105130998B publication Critical patent/CN105130998B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
CN201510618067.6A 2015-09-25 2015-09-25 库潘尼西的制备方法 Active CN105130998B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201510618067.6A CN105130998B (zh) 2015-09-25 2015-09-25 库潘尼西的制备方法
KR1020187011225A KR102104957B1 (ko) 2015-09-25 2016-07-01 코판리십의 제조방법
PCT/CN2016/088091 WO2017049983A1 (zh) 2015-09-25 2016-07-01 库潘尼西的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510618067.6A CN105130998B (zh) 2015-09-25 2015-09-25 库潘尼西的制备方法

Publications (2)

Publication Number Publication Date
CN105130998A true CN105130998A (zh) 2015-12-09
CN105130998B CN105130998B (zh) 2017-07-28

Family

ID=54716625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510618067.6A Active CN105130998B (zh) 2015-09-25 2015-09-25 库潘尼西的制备方法

Country Status (3)

Country Link
KR (1) KR102104957B1 (und)
CN (1) CN105130998B (und)
WO (1) WO2017049983A1 (und)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049983A1 (zh) * 2015-09-25 2017-03-30 苏州立新制药有限公司 库潘尼西的制备方法
CN108884496A (zh) * 2016-02-01 2018-11-23 拜耳制药股份公司 Copanlisib生物标志物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326307A2 (en) * 1988-01-23 1989-08-02 Kyowa Hakko Kogyo Co., Ltd. Novel pyridazinone derivatives and pharmaceutical preparations containing them
JP2003252875A (ja) * 2002-03-04 2003-09-10 Lotte Co Ltd 新規プリン誘導体
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯－嘧啶衍生物
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5210558B2 (ja) * 2007-07-12 2013-06-12 株式会社ブリヂストン 防振装置
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326307A2 (en) * 1988-01-23 1989-08-02 Kyowa Hakko Kogyo Co., Ltd. Novel pyridazinone derivatives and pharmaceutical preparations containing them
JP2003252875A (ja) * 2002-03-04 2003-09-10 Lotte Co Ltd 新規プリン誘導体
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯－嘧啶衍生物
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049983A1 (zh) * 2015-09-25 2017-03-30 苏州立新制药有限公司 库潘尼西的制备方法
CN108884496A (zh) * 2016-02-01 2018-11-23 拜耳制药股份公司 Copanlisib生物标志物

Also Published As

Publication number Publication date
KR20180096572A (ko) 2018-08-29
CN105130998B (zh) 2017-07-28
KR102104957B1 (ko) 2020-04-28
WO2017049983A1 (zh) 2017-03-30

Similar Documents

Publication Publication Date Title
AU2021261879B2 (en) Synthesis of N-(heteroaryl)-pyrrolo[2,3-d]pyrimidin-2-amines
ES2794639T3 (es) Forma cristalina, método de preparación y compuesto intermedio de compuesto con anillo dihidropirido
AU2019400110B2 (en) Radioactive fluorine-labeled Larotrectinib compound and preparation method therefor
CN110627801B (zh) 一类hdac抑制剂及其用途
CN107573333B (zh) 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
CN105753944B (zh) 达卡他韦及其衍生物的制备中间体
ES2837361T3 (es) Proceso para preparar compuestos de indol-carboxamida
CN105130998A (zh) 库潘尼西的制备方法
CA3129936A1 (en) Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one
CN106749259A (zh) 一种环戊基嘧啶并吡咯类化合物的合成方法
CN109608468B (zh) 一种枸橼酸托法替布杂质及其合成方法和用途
CN104910158A (zh) 具有生物活性的5,6,7,8-四氢吡啶并[3,4-d]嘧啶化合物及其制备方法和应用
CN105712919B (zh) 酰胺缩合剂在维格列汀合成方法中的应用
CN105273023B (zh) 一种阿糖胞苷5’-o-l-缬氨酸酯盐酸盐的制备方法
CN107814804A (zh) 依鲁替尼的制备方法
CN105130997A (zh) 一种库潘尼西的制备方法
CN105985317B (zh) 一种色瑞替尼的制备方法及其中间体
CN104725292A (zh) 一种(s)(-)-氨磺必利的制备方法
CN104030958A (zh) 一种（s）-1-（2-氯乙酰基）吡咯烷-2-甲腈的合成方法
CN114409727A (zh) 一种抗冠状病毒的3clpro抑制剂的制备方法
KR20210049130A (ko) 세고리식 화합물의 결정 형태 및 이의 용도
EP3257851A1 (en) Salt form and crystal form of 1,2,5 thiadiazolidin-1,1-dioxide, preparation method thereof and intermediate
Zych et al. The effect of substitution patterns on the release rates of opioid peptides DADLE and [Leu5]-enkephalin from coumarin prodrug moieties
CN113999238B (zh) 一种环-反-4-l-羟脯氨酰基-l-丝氨酸-o-氨基酸酯盐酸盐的制备方法
CN105085541A (zh) 一种普拉格雷类似物的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20200714

Address after: Hu Suzhou high tech Zone of Jiangsu province 215151 City Road No. 21 Tang Guan District

Patentee after: SUZHOU LIXIN PHARMACEUTICAL Co.,Ltd.

Address before: 215151 No. 21 West Tong Road, hi tech Development Zone, Jiangsu, Suzhou

Co-patentee before: Xu Xuenong

Patentee before: SUZHOU LIXIN PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right